Patents by Inventor Shingo Yamamoto

Shingo Yamamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10407057
    Abstract: There is provided a hybrid vehicle configured to control an engine, a first motor, a second motor and a third motor such as to be driven based on a required torque for driving. When the second motor is undrivable, the hybrid vehicle is configured to control the engine, the first motor and the third motor, such as to provide a higher state of charge of a battery than a state of charge of the battery provided when the second motor is drivable and such as to output a torque from the engine via a planetary gear to one pair of wheels accompanied with output of a torque from the first motor and output a torque from the third motor to the other pair of wheels.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: September 10, 2019
    Assignees: Toyota Jidosha Kabushiki Kaisha, Denso Corporation
    Inventors: Takahiko Hirasawa, Shingo Takinai, Yutaka Koyama, Junmin Cao, Kengou Yamamoto
  • Patent number: 10377759
    Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 13, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Hiroshi Tokura, Masakuni Kurono, Yoshinori Nomura, Shingo Hotta
  • Patent number: 10370377
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 6, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Publication number: 20190232830
    Abstract: A vehicle seat having a seat cushion and ottoman pillars attached to the seat cushion, the seat cushion can be formed in a compact manner. The vehicle seat (S) comprises a cushion frame (F1) including a pair of cushion side frames (85), a cushion front member (86) connecting front ends of the cushion side frames with each other and a cushion rear member (87). The cushion front member is provided with a pair of recesses (143) extending in a fore and aft direction, and a pair of pillar support portions (141) extending in the fore and aft direction are received in and bonded to the respective recesses, the ottoman including a pair of ottoman pillars (135) inserted into the respective pillar support portions.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Inventors: Shinya Aita, Hirotaka Takei, Masahiko Yamamoto, Shingo Kimata, Shigekazu Otake, Takahiro Mitsui, Masashi Yamashita
  • Patent number: 10358127
    Abstract: There is provided a hybrid vehicle configured to control an engine, a first motor, a second motor and a third motor such as to be driven based on a required torque for driving. When the second motor is undrivable, the hybrid vehicle is configured to control the engine, the first motor and the third motor, such as to provide a higher state of charge of a battery than a state of charge of the battery provided when the second motor is drivable and such as to output a torque from the engine via a planetary gear to one pair of wheels accompanied with output of a torque from the first motor and output a torque from the third motor to the other pair of wheels.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: July 23, 2019
    Assignees: Toyota Jidosha Kabushiki Kaisha, Denso Corporation
    Inventors: Takahiko Hirasawa, Shingo Takinai, Yutaka Koyama, Junmin Cao, Kengou Yamamoto
  • Patent number: 10350885
    Abstract: A liquid discharge device performs recording by use of a liquid discharge head including discharge ports to discharge a liquid, pressure generation elements to generate energy to be used to discharge the liquid, and pressure chambers communicating with the discharge ports. The liquid discharge device includes a control unit to control a temperature of the liquid discharge head by applying heat with heating elements arranged in divided areas of a region of the liquid discharge head where the discharge ports are arranged. When there is recording data for the discharge port in a certain one of the divided areas, the control unit causes the heating element in the divided area to generate heat, and when there is no recording data for the discharge port in the certain divided area, the control unit keeps the heating element in the certain divided area from generating heat.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 16, 2019
    Assignee: Canon Kabushiki Kaisha
    Inventors: Takatsuna Aoki, Shuzo Iwanaga, Seiichiro Karita, Kazuhiro Yamada, Shingo Okushima, Zentaro Tamenaga, Akira Yamamoto, Tatsurou Mori, Noriyasu Nagai, Akio Saito, Ryo Kasai
  • Publication number: 20190188036
    Abstract: Provided are a computer system and a program migration method capable of properly migrating programs between different computers. A first computer calculates a migration priority of each of the plurality of programs based on information which indicates weighting relative to usage of hardware resources, and operation information of hardware resources in the first computer when each of the plurality of programs is executed, and, based on hardware resource expansion schedule information which defines hardware resources of the second computer in each of a plurality of migration phases, determines migration feasibility of a program in hardware resources used in each migration phase and decides the migration phase for migrating each of the plurality of programs in order from a first migration phase of the plurality of migration phases and in order of the calculated migration priority.
    Type: Application
    Filed: August 30, 2018
    Publication date: June 20, 2019
    Inventors: Sho YAMAMOTO, Shingo MAEDA, Yuki KOIZUMI
  • Patent number: 10314844
    Abstract: Inhibitors for Bruton's Tyrosine Kinase (BTK) are disclosed as are compositions thereof, methods for their preparation, and methods for their use.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: June 11, 2019
    Assignees: GILEAD SCIENCES, INC., ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seung H. Lee, Shingo Yamamoto
  • Publication number: 20190169192
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Patent number: 10293604
    Abstract: In order to keep possible local temperature differences in a liquid ejection head small to allow stable liquid ejection performance to be achieved, temperatures in a plurality of heating areas in a liquid ejection head are discretely controlled using heating elements and temperature detection elements.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 21, 2019
    Assignee: Canon Kabushiki Kaisha
    Inventors: Takatsuna Aoki, Shuzo Iwanaga, Seiichiro Karita, Kazuhiro Yamada, Shingo Okushima, Zentaro Tamenaga, Akira Yamamoto, Tatsurou Mori, Noriyasu Nagai, Akio Saito, Masashi Hayashi, Takeshi Murase, Yuki Sawai
  • Patent number: 10293717
    Abstract: A vehicle seat having a seat cushion and ottoman pillars attached to the seat cushion, the seat cushion can be formed in a compact manner. The vehicle seat (S) comprises a cushion frame (F1) including a pair of cushion side frames (85), a cushion front member (86) connecting front ends of the cushion side frames with each other and a cushion rear member (87). The cushion front member is provided with a pair of recesses (143) extending in a fore and aft direction, and a pair of pillar support portions (141) extending in the fore and aft direction are received in and bonded to the respective recesses, the ottoman including a pair of ottoman pillars (135) inserted into the respective pillar support portions.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 21, 2019
    Assignee: TS TECH CO., LTD.
    Inventors: Shinya Aita, Hirotaka Takei, Masahiko Yamamoto, Shingo Kimata, Shigekazu Otake, Takahiro Mitsui, Masashi Yamashita
  • Patent number: 10233185
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 19, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Publication number: 20180244675
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Publication number: 20180243311
    Abstract: Inhibitors for Bruton's Tyrosine Kinase (BTK) are disclosed as are compositions thereof, methods for their preparation, and methods for their use.
    Type: Application
    Filed: February 23, 2018
    Publication date: August 30, 2018
    Inventors: Seung H. Lee, Shingo Yamamoto
  • Publication number: 20180186800
    Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.
    Type: Application
    Filed: June 21, 2016
    Publication date: July 5, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
  • Publication number: 20180170933
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Patent number: 9981966
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: May 29, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 9926322
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: March 27, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 9896453
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: February 20, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 9879013
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 30, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa